BACKGROUND: Chronic fatigue syndrome (CFS) is an illness with unknown aetiology and pathophysiology. The difference in incidence by sex observed for CFS indicates a role for oestrogen and oestrogen receptors in disease development. Furthermore, an immunomediated pathogenesis has been suggested for CFS, providing an additional connection to oestrogen, which displays immunomodular functions. AIMS: To investigate a possible association of oestrogen receptor (ER) mRNAs and two ERbeta single-nucleotide polymorphisms (SNPs) with CFS. METHODS: Messenger RNA levels of ERalpha, ERbeta wt and ERbeta cx were investigated in peripheral blood mononuclear cells from 30 patients with CFS and 36 healthy controls by quantitative real-time polymerase chain reaction. Two ERbeta SNPs were scored in the same material. RESULTS: The CFS group showed significantly lower mRNA expression levels of ERbeta wt compared with the healthy control group. No differences were observed for ERalpha or ERbeta cx between patients and controls. There were no significant differences in frequency for the investigated ERbeta SNPs between cases and controls. CONCLUSIONS: The reduced ERbeta wt expression level observed in this study is consistent with an immune-mediated pathogenesis of CFS. Additionally, the observation that ERbeta wt expression is decreased in CFS could provide an entry point to identify interesting, potentially disease-causing, candidate molecules for further study. A possible connection between oestrogen, oestrogen receptors and CFS should be evaluated further.
BACKGROUND:Chronic fatigue syndrome (CFS) is an illness with unknown aetiology and pathophysiology. The difference in incidence by sex observed for CFS indicates a role for oestrogen and oestrogen receptors in disease development. Furthermore, an immunomediated pathogenesis has been suggested for CFS, providing an additional connection to oestrogen, which displays immunomodular functions. AIMS: To investigate a possible association of oestrogen receptor (ER) mRNAs and two ERbeta single-nucleotide polymorphisms (SNPs) with CFS. METHODS: Messenger RNA levels of ERalpha, ERbeta wt and ERbeta cx were investigated in peripheral blood mononuclear cells from 30 patients with CFS and 36 healthy controls by quantitative real-time polymerase chain reaction. Two ERbeta SNPs were scored in the same material. RESULTS: The CFS group showed significantly lower mRNA expression levels of ERbeta wt compared with the healthy control group. No differences were observed for ERalpha or ERbeta cx between patients and controls. There were no significant differences in frequency for the investigated ERbeta SNPs between cases and controls. CONCLUSIONS: The reduced ERbeta wt expression level observed in this study is consistent with an immune-mediated pathogenesis of CFS. Additionally, the observation that ERbeta wt expression is decreased in CFS could provide an entry point to identify interesting, potentially disease-causing, candidate molecules for further study. A possible connection between oestrogen, oestrogen receptors and CFS should be evaluated further.
Authors: Maximillian T Follettie; Marc Pinard; James C Keith; Lili Wang; Daniel Chelsky; Clive Hayward; Paul Kearney; Pierre Thibault; Eustache Paramithiotis; Andrew J Dorner; Heather A Harris Journal: Endocrinology Date: 2005-11-03 Impact factor: 4.736
Authors: S Nilsson; S Mäkelä; E Treuter; M Tujague; J Thomsen; G Andersson; E Enmark; K Pettersson; M Warner; J A Gustafsson Journal: Physiol Rev Date: 2001-10 Impact factor: 37.312
Authors: Heather A Harris; Leo M Albert; Yelena Leathurby; Michael S Malamas; Richard E Mewshaw; Chris P Miller; Yogendra P Kharode; James Marzolf; Barry S Komm; Richard C Winneker; Donald E Frail; Ruth A Henderson; Yuan Zhu; James C Keith Journal: Endocrinology Date: 2003-10 Impact factor: 4.736
Authors: Chunyan Zhao; Eric W-F Lam; Andrew Sunters; Eva Enmark; Manuela Tamburo De Bella; R Charles Coombes; Jan-Ake Gustafsson; Karin Dahlman-Wright Journal: Oncogene Date: 2003-10-23 Impact factor: 9.867
Authors: N Kaushik; D Fear; S C M Richards; C R McDermott; E F Nuwaysir; P Kellam; T J Harrison; R J Wilkinson; D A J Tyrrell; S T Holgate; J R Kerr Journal: J Clin Pathol Date: 2005-08 Impact factor: 3.411
Authors: Suzanne D Vernon; Elizabeth R Unger; Irina M Dimulescu; Mangalathu Rajeevan; William C Reeves Journal: Dis Markers Date: 2002 Impact factor: 3.434
Authors: J R Kerr; P Christian; A Hodgetts; P R Langford; L D Devanur; R Petty; B Burke; L I Sinclair; S C M Richards; J Montgomery; C R McDermott; T J Harrison; P Kellam; D J Nutt; S T Holgate Journal: J Clin Pathol Date: 2006-08-25 Impact factor: 3.411
Authors: Stephanie L Nott; Yanfang Huang; Brian R Fluharty; Anna M Sokolov; Melinda Huang; Cathleen Cox; Mesut Muyan Journal: Curr Pharmacogenomics Person Med Date: 2008-12-01
Authors: B M Carruthers; M I van de Sande; K L De Meirleir; N G Klimas; G Broderick; T Mitchell; D Staines; A C P Powles; N Speight; R Vallings; L Bateman; B Baumgarten-Austrheim; D S Bell; N Carlo-Stella; J Chia; A Darragh; D Jo; D Lewis; A R Light; S Marshall-Gradisnik; I Mena; J A Mikovits; K Miwa; M Murovska; M L Pall; S Stevens Journal: J Intern Med Date: 2011-08-22 Impact factor: 8.989
Authors: David R Strayer; William A Carter; Bruce C Stouch; Staci R Stevens; Lucinda Bateman; Paul J Cimoch; Charles W Lapp; Daniel L Peterson; William M Mitchell Journal: PLoS One Date: 2012-03-14 Impact factor: 3.240
Authors: Phillip H Comella; Edgar Gonzalez-Kozlova; Roman Kosoy; Alexander W Charney; Irene Font Peradejordi; Shreya Chandrasekar; Scott R Tyler; Wenhui Wang; Bojan Losic; Jun Zhu; Gabriel E Hoffman; Seunghee Kim-Schulze; Jingjing Qi; Manishkumar Patel; Andrew Kasarskis; Mayte Suarez-Farinas; Zeynep H Gümüş; Carmen Argmann; Miriam Merad; Christian Becker; Noam D Beckmann; Eric E Schadt Journal: medRxiv Date: 2021-02-02
Authors: Geoffrey Chern-Yee Tan; Carlton Chu; Yu Teng Lee; Clarence Chih King Tan; John Ashburner; Nicholas W Wood; Richard Sj Frackowiak Journal: Neuroimage Date: 2020-06-25 Impact factor: 6.556